Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Kushner BS, Freeman D, Sparkman J, Salles A, Eagon JC, Eckhouse SR
Hard work and perseverance really paid off in the end
Participants can receive standard of care therapies (defined as treatment with an approved AD medication, including an acetylcholinesterase inhibitor, memantine, or an anti-amyloid monoclonal antibody, or combinations of these agents) during the trial
Approval Milestone: First-in-class entry inhibitor FDA-approved for adults with chronic Hepatitis Delta Virus (HDV) infection
Prats, C
US$ 25.48
US$ 20.04
US$ 28.47
US$ 21.37
US$ 20.85
